Prevalence of Infection and Antibiotic Susceptibility of Helicobacter pylori: An Evaluation in Public and Private Health Systems of Southern Chile
Abstract
:1. Introduction
2. Results
3. Discussion
3.1. Prevalence of H. pylori Infection
3.2. Antibiotic Susceptibility
4. Materials and Methods
4.1. Patient Recruitment
4.2. Sample Collection
4.3. Culture and Phenotypic Identification of H. pylori
4.4. DNA Extraction from Pure Culture
4.5. Total DNA Extraction from Urease Biopsy
4.6. Species Confirmation by Molecular Biology
4.7. Antibiotic Susceptibility Study
4.8. Statistical Analysis
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Otth, L.; Wilson, M.; Fernández, H.; Otth, C.; Toledo, C.; Cárcamo, V.; Rivera, P.; Ruiz, L. Isolation of Helicobacter pylori in gastric mucosa and susceptibility to five antimicrobial drugs in Southern chile. Braz. J. Microbiol. 2011, 42, 442–447. [Google Scholar] [CrossRef] [PubMed]
- Hunt, R.H.; Xiao, S.D.; Megraud, F.; Leon-Barua, R.; Bazzoli, F.; van der Merwe, S.; Vaz Coelho, L.G.; Fock, M.; Fedail, S.; Cohen, H.; et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J. Gastrointestin. Liver Dis. 2011, 20, 299–304. [Google Scholar] [PubMed]
- Porras, C.; Nodora, J.; Sexton, R.; Ferreccio, C.; Jimenez, S.; Dominguez, R.L.; Cook, P.; Anderson, G.; Morgan, D.R.; Baker, L.H.; et al. Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control 2013, 24, 209–215. [Google Scholar] [CrossRef] [PubMed]
- Laurell, A.C.; Giovanella, L. Health Policies and Systems in Latin America; Oxford University Press: Oxford, UK, 2018. [Google Scholar]
- Vásquez, F.; Paraje, G.; Estay, M. Income-related inequality in health and health care utilization in Chile, 2000–2009. Rev. Panam. Salud Publ. 2013, 33, 98–106. [Google Scholar] [CrossRef] [PubMed]
- Malfertheiner, P.; Megraud, F.; O’Morain, C.A.; Gisbert, J.P.; Kuipers, E.J.; Axon, A.T.; Bazzoli, F.; Gasbarrini, A.; Atherton, J.; Graham, D.Y.; et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut 2017, 66, 6–30. [Google Scholar] [CrossRef] [PubMed]
- De Francesco, V.; Giorgio, F.; Hassan, C.; Manes, G.; Vannella, L.; Panella, C.; Ierardi, E.; Zullo, A. Worldwide H. pylori antibiotic resistance: A systematic review. J. Gastrointestin. Liver Dis. 2010, 19, 409–414. [Google Scholar] [PubMed]
- Boyanova, L.; Mitov, I. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev. Anti Infect. Ther. 2010, 8, 59–70. [Google Scholar] [CrossRef]
- Papastergiou, V.; Georgopoulos, S.D.; Karatapanis, S. Treatment of Helicobacter pylori infection: Past, present and future. World J. Gastrointest. Pathophysiol. 2014, 5, 392–399. [Google Scholar] [CrossRef]
- Lee, J.W.; Kim, N.; Kim, J.M.; Nam, R.H.; Chang, H.; Kim, J.Y.; Shin, C.M.; Park, Y.S.; Lee, D.H.; Jung, H.C. Prevalence of Primary and Secondary Antimicrobial Resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013, 18, 206–214. [Google Scholar] [CrossRef]
- Khoder, G.; Muhammad, J.S.; Mahmoud, I.; Soliman, S.S.M.; Burucoa, C. Prevalence of Helicobacter pylori and Its Associated Factors among Healthy Asymptomatic Residents in the United Arab Emirates. Pathogens 2019, 8, 44. [Google Scholar] [CrossRef]
- Csendes, A.; Figueroa, M. Situación del cáncer gástrico en el mundo y en Chile. Rev. Chil. Cirugía 2017, 69, 502–507. [Google Scholar] [CrossRef]
- Csendes, A.; Smok, G.; Medina, E.; Salgado, I.; Rivera, R.; Quitral, M. Clinical course characteristics of gastric cancer 1958–1990. Rev. Med. Chil. 1992, 120, 36–42. [Google Scholar] [PubMed]
- Ahmed, K.S.; Khan, A.A.; Ahmed, I.; Tiwari, S.K.; Habeeb, A.; Ahi, J.D.; Abid, Z.; Ahmed, N.; Habibullah, C.M. Impact of household hygiene and water source on the prevalence and transmission of Helicobacter pylori: A South Indian perspective. Singap. Med. J. 2007, 48, 543–549. [Google Scholar]
- Serrano, H.C.; Villagrán, T.A.; Harris, D.P.R. Helicobacter pylori: Una causa no tradicional de deficiencia de hierro y anemia. Rev. Chil. Pediatría 2012, 83, 13–23. [Google Scholar] [CrossRef]
- Aravena, L.P.; Inostroza, P.M. ¿Salud Pública o Privada? Los factores más importantes al evaluar el sistema de salud en Chile. Rev. Méd. Chile 2015, 143, 244–251. [Google Scholar] [CrossRef]
- Burucoa, C.; Axon, A. Epidemiology of Helicobacter pylori infection. Helicobacter 2017, 22, e12403. [Google Scholar] [CrossRef]
- Ferreccio, C.; Rollán, A.; Harris, P.R.; Serrano, C.; Gederlini, A.; Margozzini, P.; Gonzalez, C.; Aguilera, X.; Venegas, A.; Jara, A. Gastric cancer is related to early Helicobacter pylori infection in a high-prevalence country. Cancer Epidemiol. Biomark. Prev. 2007, 16, 662–667. [Google Scholar] [CrossRef]
- Araya, O.J.C.; Villaseca, H.M.A.; Roa, E.I.; Roa, S.J.C. Helicobacter pylori y gastritis crónica: Relación entre infección y actividad inflamatoria en población de alto riesgo de cáncer gástrico. Rev. Méd. Chile 2000, 128, 259–265. [Google Scholar] [CrossRef]
- Da Costa, D.; Guidotti, F.; Cabello, N.; Trigo, F.; Contreras, C.; Vergara, F.; Miranda, J.P.; Montenegro, C.; Muñoz, P.; Berger, Z. Helicobacter pylori infection detected during upper gastrointestinal endoscopy. Rev Med. Chile 2018, 146, 555–561. [Google Scholar] [CrossRef]
- Baena Diez, J.M.; García Lareo, M.; Martí Fernández, J.; León Marín, I.; Muñiz Llama, D.; Teruel Gila, J.; Baena Díez, J.M.; Rams Rams, F.; Hernández Ibáñez, M.R. Prevalence of Helicobacter pylori infection in primary care: Sero-epidemiological study. Aten. Primaria 2002, 29, 553–557. [Google Scholar] [CrossRef]
- Breuer, T.; Sudhop, T.; Hoch, J.; Sauerbruch, T.; Malfertheiner, P. Prevalence of and risk factors for Helicobacter pylori infection in the western part of Germany. Eur. J. Gastroenterol. Hepatol. 1996, 8, 47–52. [Google Scholar] [CrossRef] [PubMed]
- Kodaman, N.; Pazos, A.; Schneider, B.G.; Piazuelo, M.B.; Mera, R.; Sobota, R.S.; Sicinschi, L.A.; Shaffer, C.L.; Romero-Gallo, J.; de Sablet, T.; et al. Human and Helicobacter pylori coevolution shapes the risk of gastric disease. Proc. Natl. Acad. Sci. USA 2014, 111, 1455–1460. [Google Scholar] [CrossRef] [PubMed]
- Murray, L.J.; McCrum, E.E.; Evans, A.E.; Bamford, K.B. Epidemiology of Helicobacter pylori infection among 4742 randomly selected subjects from Northern Ireland. Int. J. Epidemiol. 1997, 26, 880–887. [Google Scholar] [CrossRef] [PubMed]
- Höök-Nikanne, J. Effect of alcohol consumption on the risk of Helicobacter pylori infection. Digestion 1991, 50, 92–98. [Google Scholar] [CrossRef] [PubMed]
- Kunstmann, E.; Hardt, C.; Treitz, H.; Suerbaum, S.; Faller, G.; Peitz, U.; Schmiegel, W.; Epplen, J.T. In the European population HLA-class II genes are not associated with Helicobacter pylori infection. Eur. J. Gastroenterol. Hepatol. 2002, 14, 49–53. [Google Scholar] [CrossRef]
- Graham, D.Y.; Malaty, H.M.; Evans, D.G.; Evans, D.J.; Klein, P.D.; Adam, E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 1991, 100, 1495–1501. [Google Scholar] [CrossRef]
- Malaty, H.M.; El-Kasabany, A.; Graham, D.Y.; Miller, C.C.; Reddy, S.G.; Srinivasan, S.R.; Yamaoka, Y.; Berenson, G.S. Age at acquisition of Helicobacter pylori infection: A follow-up study from infancy to adulthood. Lancet 2002, 359, 931–935. [Google Scholar] [CrossRef]
- Eyheramendy, S.; Martinez, F.I.; Manevy, F.; Vial, C.; Repetto, G.M. Genetic structure characterization of Chileans reflects historical immigration patterns. Nat. Commun. 2015, 17, 6472. [Google Scholar] [CrossRef]
- Greenberg, E.; Anderson, G.R.; Morgan, D.; Torres, J.; Chey, W.; Bravo, L.; Dominguez, R.; Ferreccio, C.; Herrero, R.C.; Lazcano-Ponce, E.; et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: A randomised trial. Lancet 2011, 378, 507–514. [Google Scholar] [CrossRef]
- Hofmann, E.; Bohn, B.; Sandoval, C.; Carrasco, K.; Ramírez, K. Evaluación de triterapia en helicobacter pylori en po blación adulta de araucanía. Gastroenterologia Latinoamerciana 2018, 29 (Suppl. 2). Available online: https://gastrolat.org/tl28-presencia-de-neisseria-sp-ureasa-positivo-aisladas-en-pacientes-con-refractariedad-al-tratamiento-de-erradicacion-para-h-pylori/ (accessed on 13 June 2019).
- González, C.; García, A.; Daroch, F.; Kawaguchi, F.; Solar, H.; Rivera, N.; Vega, E. In vitro antimicrobial susceptibility of Helicobacter pylori strains: Isolation of strains resistant to clarithromycin. Rev. Med. Chile 2001, 129, 643–646. [Google Scholar]
- Vallejos, C.; Garrido, L.; Cáceres, D.; Madrid, A.M.; Defilippi, C.; Toledo, H. Prevalence of metronidazole, clarithromycin and tetracycline resistance in Helicobacter pylori isolated from Chilean patients. Rev. Med. Chile 2007, 135, 287–293. [Google Scholar] [PubMed]
- Megraud, F.; Coenen, S.; Versporten, A.; Kist, M.; Lopez-Brea, M.; Hirschl, A.M.; Andersen, L.P.; Goossens, H.; Glupczynski, Y.; Participants, S.G. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013, 62, 34–42. [Google Scholar] [CrossRef] [PubMed]
- Thung, I.; Aramin, H.; Vavinskaya, V.; Gupta, S.; Park, J.Y.; Crowe, S.E.; Valasek, M.A. Review article: The global emergence of Helicobacter pylori antibiotic resistance. Aliment. Pharm. Ther. 2016, 43, 514–533. [Google Scholar] [CrossRef] [PubMed]
- Pajares García, J.M.; Pajares-Villarroya, R.; Gisbert, J.P. Helicobacter pylori: Resistencia a los antibióticos. Rev. Española Enferm. Dig. 2007, 99, 63–70. [Google Scholar] [CrossRef] [PubMed]
- Wani, F.A.; Bashir, G.; Khan, M.A.; Zargar, S.A.; Rasool, Z.; Qadri, Q. Antibiotic resistance in Helicobacter pylori: A mutational analysis from a tertiary care hospital in Kashmir, India. Indian J. Med. Microbiol. 2018, 36, 265–272. [Google Scholar] [PubMed]
- Tveit, A.H.; Bruce, M.G.; Bruden, D.L.; Morris, J.; Reasonover, A.; Hurlburt, D.A.; Hennessy, T.W.; McMahon, B. Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008. J. Clin. Microbiol. 2011, 49, 3638–3643. [Google Scholar] [CrossRef] [PubMed]
- Tuan, V.P.; Narith, D.; Tshibangu-Kabamba, E.; Dung, H.D.Q.; Viet, P.T.; Sokomoth, S.; Binh, T.T.; Sokhem, S.; Tri, T.D.; Ngov, S.; et al. A Next-Generation Sequencing-Based Approach to Identify Genetic Determinants of Antibiotic Resistance in Cambodian. J. Clin. Med. 2019, 8, 858. [Google Scholar] [CrossRef]
- Eisig, J.N.; Silva, F.M.; Barbuti, R.C.; Navarro-Rodriguez, T.; Moraes-Filho, J.P.; Pedrazzoli, J. Helicobacter pylori antibiotic resistance in Brazil: Clarithromycin is still a good option. Arq. Gastroenterol. 2011, 48, 261–264. [Google Scholar] [CrossRef]
- Mochizuki Tamayo, H.; Noriega Aldave, A.P. Antimicrobial susceptibility of Helicobacter pylori to levofloxacin determined in a miniwell format and disk diffusion tests using egg yolk agar. Rev. Gastroenterol. Peru 2011, 31, 224–229. [Google Scholar]
- Bluemel, B.; Goelz, H.; Goldmann, B.; Grüger, J.; Hamel, H.; Loley, K.; Ludolph, T.; Meyer, J.; Miehlke, S.; Mohr, A.; et al. Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018. Clin. Microbiol. Infect. 2019, in press. [Google Scholar] [CrossRef]
- Fernández-Reyes, M.; Tamayo, E.; Rojas-Rengifo, D.; Fischer, W.; Carrasco-García, E.; Alonso, M.; Lizasoain, J.; Bujanda, L.; Cosme, Á.; Montes, M. Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain. Eur. J. Clin. Investig. 2019, 49, e13150. [Google Scholar] [CrossRef] [PubMed]
- Wang, D.; Guo, Q.; Yuan, Y.; Gong, Y. The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer. BMC Microbiol. 2019, 19, 152. [Google Scholar] [CrossRef] [PubMed]
- Camargo, M.C.; García, A.; Riquelme, A.; Otero, W.; Camargo, C.A.; Hernandez-García, T.; Candia, R.; Bruce, M.G.; Rabkin, C.S. The problem of Helicobacter pylori resistance to antibiotics: A systematic review in Latin America. Am. J. Gastroenterol. 2014, 109, 485–495. [Google Scholar] [CrossRef] [PubMed]
- Picoli, S.U.; Mazzoleni, L.E.; Fernández, H.; De Bona, L.R.; Neuhauss, E.; Longo, L.; Prolla, J.C. Resistance to amoxicillin, clarithromycin and ciprofloxacin of Helicobacter pylori isolated from Southern Brazil patients. Rev. Inst. Med. Trop. São Paulo 2014, 56, 197–200. [Google Scholar] [CrossRef]
- The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 9.0. 2019. Available online: http://www.eucast.org. (accessed on 2 October 2019).
- Chacón, J.A.R.; Guerrero, K.V.G.; Tigselema, R.E.P.; Quirós, G.F.P.; Ñacato, E.J.M.; Vanoni, L.S.E. Susceptibilidad antibiótica de Helicobacter pylori: Un estudio de prevalencia en pacientes con dispepsia en Quito, Ecuador. Rev. Colomb. Gastroenterol. 2017, 32, 305–310. [Google Scholar] [CrossRef]
- Alarcón, T.; Urruzuno, P.; Martínez, M.J.; Domingo, D.; Llorca, L.; Correa, A.; López-Brea, M. Antimicrobial susceptibility of 6 antimicrobial agents in Helicobacter pylori clinical isolates by using EUCAST breakpoints compared with previously used breakpoints. Enferm. Infecc. Microbiol. Clin. 2017, 35, 278–282. [Google Scholar] [CrossRef]
- Baroni, M.R.; Bucci, P.; Giani, R.N.; Giusti, A.; Tedeschi, F.A.; Salvatierra, E.; Barbaglia, Y.; Jimenez, F.; Zalazar, F.E. Usefulness of rapid urease test samples for molecular analysis of clarithromycin resistance in Helicobacter pylori. Rev. Argent. Microbiol. 2018, 50, 359–364. [Google Scholar] [CrossRef]
- Wormwood, T.; Parra, Á.; Bresky, G.; Madariaga, J.A.; Häberle, S.; Flores, J.; Bernal, G. Prevalencia de cepas cagA-positivo en la región de Coquimbo, determinada mediante nested-qPCR en muestras fecales. Rev. Médica Chile 2018, 146, 596–602. [Google Scholar] [CrossRef]
- Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Approved Standard. Twenty-Second Informational Supplement; CLSI Document M100-S26; CLSI: Wayne, PA, USA, 2016. [Google Scholar]
Variables | Total, n = 229 (n (%)) | Private, n = 86 (n (%)) | Public, n = 143 (n (%)) | p-Value |
---|---|---|---|---|
Age (years) | 50.68 ± 16.85 | 46.27 ± 15.82 | 53.20 ± 17.02 | 0.344 |
Sex (male/female) | 82 (35.80%)/147 (64.17%) | 34 (39.53%)/52 (60.46%) | 48 (33.56%)/95 (66.43%) | 0.362 |
Mapuche ethnicity | 53 (23.14%) | 13 (5.11%) | 30 (20.97%) | 0.025* |
Rural residence | 44 (19.21%) | 11 (12.79%) | 33 (23.07%) | 0.050* |
Education level ≤12 years | 132 (57.64%) | 26 (30.23%) | 106(74.12%) | <0.001* |
National health insurance (FONASA) | 188 (82.09%) | 48 (55.81%) | 140 (97.90%) | <0.001* |
Family group ≥5 members | 29 (12.66%) | 11 (12.79%) | 18 (12.58%) | 0.964 |
Smoker | 57 (24.89%) | 27 (31.39%) | 30 (20.97%) | 0.129 |
Drinker | 104 (45.41%) | 58 (67.44%) | 46 (32.16%) | <0.001* |
Previous infection | 52 (22.70%) | 25 (29.06%) | 27 (18.88%) | 0.075 |
Previous treatment | 31 (13.53%) | 17 (19.32%) | 14 (9.93%) | 0.046* |
Relative with GC | 76 (33.18%) | 30 (34.88%) | 46 (32.16%) | 0.673 |
Total, n = 229 (n (%)) | Private, n = 86 (n (%)) | Public, n = 143 (n (%)) | p-Value | |
---|---|---|---|---|
Urease positive | 104 (45.41%) | 38 (44.18%) | 66 (46.15%) | 0.592 |
H. pylori positive | 90 (39.30%) | 32 (37.20%) | 58 (40.55%) | 0.472 |
Background | Infected Patients n = 104 (n (%)) | Non Infected Patients n = 125 (n (%)) | Odds Ratio (CI 95%) | p-Value |
---|---|---|---|---|
Age (years) | 51.16 ± 16.85 | 52.97 ± 15.91 | 0.98 (0.96–1.00) | 0.095 |
Sex (male/female) | 34 (32.69%)/70 (67.30%) | 48 (38.04%)/77 (61.60%) | 0.71 (0.38–1.34) | 0.303 |
Mapuche ethnicity | 32 (30.76%) | 24 (19.20%) | 2.30 (1.14–4.78) | 0.026* |
Rural residence | 21 (20.19%) | 21 (16.80%) | 1.00 (0.43–2.33) | 0.982 |
Education level ≤12 years | 59 (56.73%) | 68 (54.40%) | 0.70 (0.34–1.47) | 0.354 |
National health insurance (FONASA) | 82 (78.84%) | 94 (75.20%) | 1.33 (0.55–3.17) | 0.519 |
Family group ≥5 members | 11 (10.57%) | 17 (13.60%) | 0.52 (0.21–1.28) | 0.161 |
Smoker | 26 (25.00%) | 28 (22.40%) | 1.18 (0.58–2.37) | 0.642 |
Drinker | 50 (48.07%) | 48 (38.40%) | 1.26 (0.66–2.38) | 0.470 |
Previous infection | 19 (18.26%) | 30 (24.00%) | 0.62 (0.23–1.69) | 0.360 |
Previous treatment | 11 (10.57%) | 20 (16.00%) | 0.91 (0.27–3.08) | 0.887 |
Relative with GC | 38 (36.53%) | 37 (29.60%) | 1.07 (0.57–2.01) | 0.811 |
Antibiotics | Total, n = 44 (n (%)) | Private, n = 14 (n (%)) | Public, n = 30 (n (%)) | p-Value |
---|---|---|---|---|
Amoxicillin | 16 (36.30%)/5 (11.30%) * | 3 (21.30%)* | 2 (6.90%)* | 0.164 |
Clarithromycin | 18 (40.90%) | 8 (57.10%) | 10 (33.30%) | 0.149 |
Levofloxacin | 19 (43.10%) | 2 (14.30%) | 17 (56.60%) | 0.031** |
Metronidazole | 36 (81.80%) | 12 (85.70%) | 24 (80.00%) | 0.607 |
Tetracycline | 6 (13.60%) | 2 (14.30%) | 4 (13.30%) | 0.932 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Oporto, M.; Pavez, M.; Troncoso, C.; Cerda, A.; Hofmann, E.; Sierralta, A.; Rios, E.; Coppelli, L.; Barrientos, L. Prevalence of Infection and Antibiotic Susceptibility of Helicobacter pylori: An Evaluation in Public and Private Health Systems of Southern Chile. Pathogens 2019, 8, 226. https://doi.org/10.3390/pathogens8040226
Oporto M, Pavez M, Troncoso C, Cerda A, Hofmann E, Sierralta A, Rios E, Coppelli L, Barrientos L. Prevalence of Infection and Antibiotic Susceptibility of Helicobacter pylori: An Evaluation in Public and Private Health Systems of Southern Chile. Pathogens. 2019; 8(4):226. https://doi.org/10.3390/pathogens8040226
Chicago/Turabian StyleOporto, Marcelo, Monica Pavez, Claudia Troncoso, Alvaro Cerda, Edmundo Hofmann, Armando Sierralta, Eddy Rios, Luis Coppelli, and Leticia Barrientos. 2019. "Prevalence of Infection and Antibiotic Susceptibility of Helicobacter pylori: An Evaluation in Public and Private Health Systems of Southern Chile" Pathogens 8, no. 4: 226. https://doi.org/10.3390/pathogens8040226